- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04205552
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)
August 10, 2023 updated by: University Hospital, Essen
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response
The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
90
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chiara Nicolini, PhD
- Phone Number: 0049 201 723 44708
- Email: chiara.nicolini@uk-essen.de
Study Locations
-
-
-
Hasselt, Belgium
- Recruiting
- Jessa Hospital Hasselt
-
-
-
-
-
Essen, Germany
- Recruiting
- University Hospital Essen
-
Heidelberg, Germany, 69126
- Recruiting
- Thoraxklinik Heidelberg gGmbH-Universitätsklinikum Heidelberg
-
-
-
-
-
Amsterdam, Netherlands
- Recruiting
- Netherlands Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with histologically confirmed non-small cell lung cancer (NSCLC) eligible for anatomic resection (Clinical stages I B, II and selected stage III A)
- Eastern Cooperative Oncology Group (ECOG) ≤ 1
- Sufficient pulmonary function to undergo curative lung cancer surgery
- Adequate hematological, hepatic and renal function parameters:
- Sufficient cardiac left ventricular defined as left ventricular ejection fraction (LVEF) ≥ 50% documented either by echocardiography or multigated acquisition scan (MUGA)
- Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures
Exclusion Criteria:
- Active or history of autoimmune disease or immune deficiency
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration
- Subjects who have undergone organ transplant or allogeneic stem cell transplantation
- Uncontrolled or significant cardiovascular disease
- Patients with active neurological disease
- Active malignancy or a prior malignancy within the past 3 years
- Receipt of live attenuated vaccine within 30 days prior to the first dose of study medication
- Peripheral polyneuropathy NCI CTCAE Grade ≥ 2
- History of gastric perforation or fistulae in past 6 months
- Serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment.
- The patient has undergone major surgery within 28 days prior to enrollment except staging mediastinoscopy, diagnostic Video Assisted Thoracoscopic Surgery (VATS) or implantation of a venous port-system.
- Any other concurrent preoperative antineoplastic treatment including irradiation
- Pregnant/Breastfeeding women
- Subjects with history of severe toxicity or life-threatening toxicity (grade 3 or 4) related to prior immune therapy
- Prior treatment with Lymphocyte-activation gene 3 (LAG-3) targeting Agent
- Previous treatment with Nivolumab or Relatlimab
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nivolumab
Nivolumab 2 cycles, every two weeks (q2w) o Nivolumab 240 mg i.v. over 30 min |
Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
|
Experimental: Nivolumab/Relatlimab (80 mg)
Nivolumab/Relatlimab (80 mg) 2 cycles, every two weeks (q2w)
|
Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
|
Experimental: Nivolumab/Relatlimab (240 mg)
Nivolumab/Relatlimab (240 mg) 2 cycles, every two weeks (q2w)
|
Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Feasibility of four weeks of preoperative immunotherapy with Nivolumab, Nivolumab plus Relatlimab (80 mg), and Nivolumab plus Relatlimab (240 mg)
Time Frame: Within 43 days after first study medication
|
Within 43 days after first study medication
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimation of pathological tumor response rate
Time Frame: Within 43 days after first study medication (day of surgery)
|
Within 43 days after first study medication (day of surgery)
|
|
Estimation of curative (R0) resection rate
Time Frame: Within 43 days after first study medication (day of surgery)
|
Within 43 days after first study medication (day of surgery)
|
|
Objective radiological response rate
Time Frame: After 3, 6, 9 and 12 months post-surgery
|
Objective radiological response rate per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
|
After 3, 6, 9 and 12 months post-surgery
|
Disease-free survival rate at 12 months
Time Frame: 12 months
|
Assessment of disease-free survival rate at 12 months per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
|
12 months
|
Overall survival rate at 12 months
Time Frame: 12 months
|
12 months
|
|
Morbidity
Time Frame: within 90 days after surgery
|
Estimation of morbidity within 90 days after surgery
|
within 90 days after surgery
|
Mortality
Time Frame: within 90 days after surgery
|
Estimation of mortality within 90 days after surgery
|
within 90 days after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Martin Schuler, Prof. Dr., University Hospital, Essen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2020
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
December 16, 2019
First Submitted That Met QC Criteria
December 17, 2019
First Posted (Actual)
December 19, 2019
Study Record Updates
Last Update Posted (Actual)
August 14, 2023
Last Update Submitted That Met QC Criteria
August 10, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Pharmaceutical Solutions
- Relatlimab
Other Study ID Numbers
- CA224-063
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC, Stage I
-
Vastra Gotaland RegionAstraZenecaRecruitingNSCLC, Stage IFinland, Norway, Sweden
-
Xiaorong DongUnknownHealthy Subjects | NSCLC Stage IV | NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage IIChina
-
The First Affiliated Hospital of Guangzhou Medical...RecruitingNSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage IIChina
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Amsterdam UMC, location VUmcUnknown
-
The Netherlands Cancer InstituteAstraZenecaUnknown
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Spanish Lung Cancer GroupCompleted
-
Niguarda HospitalUniversity of Turin, Italy; Fondazione del Piemonte per l'OncologiaCompleted
-
Shanghai Chest HospitalThe Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...RecruitingNSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIICChina
Clinical Trials on Nivolumab 10 MG/ML Intravenous Solution
-
Sheba Medical CenterProf. Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, Tel...RecruitingAdvanced Glioblastoma | MGMT-Unmethylated Glioblastoma | Metastatic Melanoma in the Central Nervous SystemIsrael
-
Universitair Ziekenhuis BrusselActive, not recruiting
-
Jules Bordet InstituteRecruitingRectal Cancer Stage II | Rectal Cancer Stage IIIBelgium, France
-
University Hospital, Strasbourg, FranceBristol-Myers SquibbCompleted
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbWithdrawn
-
Hospital Universitario Ramon y CajalTerminated
-
Gruppo Oncologico Italiano di Ricerca ClinicaBioikos Ambiente Srl; Istituto Toscano Tumori; Temas srl; Mipharm S.p.A.; Bristol...Active, not recruitingSquamous Non-small Cell Lung CancerItaly
-
Augusta UniversityTerminatedSmall Cell Lung Carcinoma | Small-cell Lung CancerUnited States
-
Baylor College of MedicinePharmacosmos Therapeutics, Inc.RecruitingAnemia, Iron Deficiency | Uterine BleedingUnited States
-
Baxalta now part of ShireAlzheimer's Disease Cooperative Study (ADCS)CompletedAlzheimer´s DiseaseUnited States, Canada